Nanobiotix is a late stage clinical company pioneering nanomedicine for more than a decade. We intend to significantly change the outcomes for cancer patients following a different path than other Pharma or Biotech companies: a new way to treat patients thanks to nanophysics at the heart of the cell.
Nanobiotix operates worldwide from the headquarters based in Paris, France and affiliate office in Cambridge, MA, USA. Nanobiotix has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.
We develop first-in-class products with the aim to provide a maximum benefit with a minimum change in the medical practice in order to limit the hurdle of healthcare cost.
Nano Therapy Market provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market. Posted via Industry Today. Follow us on Twitter @IndustryToday